ArticleFrontiers in immunology2025

Efficacy and safety of ruxolitinib in adult patients with refractory rheumatic disease-associated macrophage activation syndrome.

Jingjing Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.